Amgen’s Imdelltra Hits Primary Endpoint in Phase III SCLC Trial

Amgen’s investigational therapy Imdelltra (tarlatamab-dlle) has achieved its primary endpoint in the global Phase III DeLLphi-304 trial for patients with small cell lung cancer (SCLC) who progressed following platinum-based chemotherapy. The open-label, randomized, controlled study demonstrated a significant improvement in overall survival (OS) compared to standard-of-care (SOC) chemotherapy, which included topotecan, amrubicin, or lurbinectedin depending on the region.

Imdelltra is an immunotherapy developed by Amgen that targets delta-like ligand 3 (DLL3), a protein commonly expressed in SCLC but largely absent in healthy tissue. By activating T cells to attack DLL3-positive cancer cells, the therapy offers a targeted approach for a disease known for its aggressiveness and limited treatment options.

The safety profile observed in the trial remained consistent with previous data. These promising results position Imdelltra as a potential new standard of care. Additional DeLLphi trials are underway exploring various treatment regimens.

22-04-2025